Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
poseltinib + rituximab + lenalidomide
- Development stage
- Phase 2
- Lead developer
- NOBO Medicine
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Poseltinib + rituximab + lenalidomide is an investigational drug combination currently evaluated for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL)[4]. Poseltinib is an oral Janus kinase (JAK) inhibitor that targets multiple isoforms including JAK1 and JAK2. Rituximab is a monoclonal antibody against CD20, mediating cell death via antibody-dependent cellular cytotoxicity (ADCC) and direct apoptosis. Lenalidomide is an immunomodulatory agent that enhances T-cell and NK-cell activity, also inducing apoptosis in malignant cells through cereblon-dependent mechanisms and modulating cytokine production[3][4]. The rationale for combining these modalities is synergistic immune activation and tumor cell targeting, as shown in mechanistic and early clinical studies for similar regimens[4]. This regimen is being studied in a prospective, open-label, multicenter phase 2 trial.
- Other names
- poseltinib + rituximab + lenalidomide
02
Targets
BTK (Bruton tyrosine kinase)CD20 (B-lymphocyte antigen CD20)CRBN (Cereblon)JAK1 (Janus kinase 1)JAK2 (Janus kinase 2)
Beyond the preview
Go deeper on poseltinib + rituximab + lenalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on poseltinib + rituximab + lenalidomide.